Regenxbio Inc
RGNXBuild a strategy around RGNX
Regenxbio Inc AI Insights
Informational only. Not investment advice.Snapshot
- R&D spend of 219M TTM is 136% of revenue (161M) - burning cash to advance gene therapy pipeline with no near-term profitability path.[Research and Development]
- Gross profit up 103% YoY while 5Y revenue CAGR is -21% - licensing/milestone revenue volatility, not sustainable growth.[Gross Profit 1Y Growth]
- Cash of 59M with FCF burn of -106M TTM implies ~7 months runway without additional financing or milestone payments.[Free Cash Flow]
Watch Triggers
- Cash and Equivalents: Falls below 40M or financing announced — Sub-40M triggers survival mode; dilution timing critical for existing shareholders.
- Total Revenue: Quarterly revenue exceeds 60M (indicating major milestone) — Lumpy licensing revenue; single deal can extend runway 12+ months.
- Research and Development: Drops below 180M annualized — R&D cuts signal pipeline prioritization or distress - changes risk profile.
Bull Case
87% gross margin TTM with 207M working capital provides cushion; any pipeline success or licensing deal could transform valuation at 2.8x P/S.
AAV gene therapy platform has strategic value; 82M investment sales TTM shows ability to monetize assets when needed.
Bear Case
Operating margin of -96% TTM with -57% ROIC indicates severe value destruction; 42M interest expense consumes 26% of revenue.
5Y revenue decline of -21% CAGR vs industry median +7% growth signals failed commercialization strategy.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage RGNX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Cash runway crisis will force dilutive financing or partnership within 12 months.
- 59M cash vs 106M annual FCF burn
- R&D at 219M cannot be materially cut without killing pipeline
- Debt/equity at 0.47 limits borrowing capacity
Valuation Context
Caveats
Public Strategies Rankings
See how Regenxbio Inc ranks across different investment strategies.
Leverage RGNX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
RGNX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$401.62M | — | ||
$419.33M | — | ||
0.00 | — | ||
$161.32M | +91.3% | — | |
$-3.46 | — | ||
-96.0% | +193.0% | — | |
-110% | +172.9% | — | |
$-106.28M | — | ||
-76.9% | -5.0% | — | |
Beta 5Y (Monthly) | unknown | — |
RGNX Dividend History
RGNX Stock Splits
RGNX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/06/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/12/25 | 03/31/25 | 10-Q | |
03/13/25 | 12/31/24 | 10-K | |
11/06/24 | 09/30/24 | 10-Q | |
08/01/24 | 06/30/24 | 10-Q | |
05/08/24 | 03/31/24 | 10-Q | |
02/27/24 | 12/31/23 | 10-K | |
11/08/23 | 09/30/23 | 10-Q | |
08/02/23 | 06/30/23 | 10-Q | |
05/03/23 | 03/31/23 | 10-Q | |
02/28/23 | 12/31/22 | 10-K | |
11/03/22 | 09/30/22 | 10-Q | |
08/03/22 | 06/30/22 | 10-Q | |
05/04/22 | 03/31/22 | 10-Q | |
03/01/22 | 12/31/21 | 10-K | |
11/02/21 | 09/30/21 | 10-Q | |
08/09/21 | 06/30/21 | 10-Q | |
05/05/21 | 03/31/21 | 10-Q | |
03/01/21 | 12/31/20 | 10-K | |
11/04/20 | 09/30/20 | 10-Q | |
08/06/20 | 06/30/20 | 10-Q | |
05/07/20 | 03/31/20 | 10-Q | |
02/26/20 | 12/31/19 | 10-K | |
11/05/19 | 09/30/19 | 10-Q | |
08/07/19 | 06/30/19 | 10-Q | |
05/07/19 | 03/31/19 | 10-Q | |
02/27/19 | 12/31/18 | 10-K | |
11/07/18 | 09/30/18 | 10-Q | |
08/08/18 | 06/30/18 | 10-Q | |
05/08/18 | 03/31/18 | 10-Q | |
03/06/18 | 12/31/17 | 10-K | |
11/08/17 | 09/30/17 | 10-Q | |
08/08/17 | 06/30/17 | 10-Q | |
05/09/17 | 03/31/17 | 10-Q | |
03/07/17 | 12/31/16 | 10-K | |
11/09/16 | 09/30/16 | 10-Q | |
08/09/16 | 06/30/16 | 10-Q | |
05/05/16 | 03/31/16 | 10-Q | |
03/03/16 | 12/31/15 | 10-K | |
11/05/15 | 09/30/15 | 10-Q | |
09/17/15 | 06/30/15 | 424B4 | |
05/05/16 | 03/31/15 | 10-Q | |
09/17/15 | 12/31/14 | 424B4 | |
11/05/15 | 09/30/14 | 10-Q |